Addison Advisors LLC Has $33,000 Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Addison Advisors LLC lowered its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 84.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 68 shares of the medical equipment provider’s stock after selling 363 shares during the quarter. Addison Advisors LLC’s holdings in Intuitive Surgical were worth $33,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Ridgewood Investments LLC acquired a new stake in Intuitive Surgical in the 2nd quarter valued at about $26,000. Godsey & Gibb Inc. lifted its holdings in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares in the last quarter. Creekmur Asset Management LLC increased its stake in shares of Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares during the period. LGT Financial Advisors LLC raised its position in shares of Intuitive Surgical by 415.4% during the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 54 shares during the last quarter. Finally, Delos Wealth Advisors LLC lifted its stake in shares of Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $535.75 on Tuesday. The company has a market cap of $190.82 billion, a PE ratio of 86.13, a PEG ratio of 5.27 and a beta of 1.39. The stock has a 50-day simple moving average of $493.92 and a 200 day simple moving average of $452.79. Intuitive Surgical, Inc. has a 52-week low of $281.12 and a 52-week high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The company had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. On average, research analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now owns 821 shares of the company’s stock, valued at approximately $402,519.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, General Counsel Gary Loeb sold 300 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $475.00, for a total transaction of $142,500.00. Following the transaction, the general counsel now directly owns 1,595 shares in the company, valued at $757,625. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now owns 821 shares of the company’s stock, valued at $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,006 shares of company stock valued at $33,727,766 in the last three months. 0.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ISRG has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus boosted their price target on shares of Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. The Goldman Sachs Group set a $604.00 price objective on shares of Intuitive Surgical in a research note on Friday, October 18th. Raymond James upped their target price on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Finally, Evercore ISI reaffirmed a “cautious” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.